Given Nrf2's available location at the pivotal point of various pathways, pharmacologic manipulations of downstream effectors or upstream regulators of Nrf2 signaling could produce significant anti-tumor effects and synergize with already established drugs [219]. The gene discussed is NFE2L2; the disease is neoplasm.